Papamichael, K., Vajravelu, R. K., Vaughn, B. P., Osterman, M. T., & Cheifetz, A. S. (2018). Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. J Crohns Colitis.
Citação norma ChicagoPapamichael, Konstantinos, Ravy K. Vajravelu, Byron P. Vaughn, Mark T. Osterman, and Adam S. Cheifetz. "Proactive Infliximab Monitoring Following Reactive Testing Is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease." J Crohns Colitis 2018.
Citação norma MLAPapamichael, Konstantinos, et al. "Proactive Infliximab Monitoring Following Reactive Testing Is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease." J Crohns Colitis 2018.